BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38439529)

  • 1. β-Sitosterol attenuates anlotinib resistance in non-small cell lung cancer cells by inhibiting miR-181a-3p/SHQ1 signaling.
    Wang LH; Sun YH; Liu H; Yang X; Wen Z; Tian XF
    Chem Biol Drug Des; 2024 Mar; 103(3):e14493. PubMed ID: 38439529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astragaloside IV Overcomes Anlotinib Resistance in Non-small Cell Lung Cancer through miR-181a-3p/UPR-ERAD Axis.
    Wang L; Sun T; Yang X; Wen Z; Sun Y; Liu H
    Curr Comput Aided Drug Des; 2024 Jan; ():. PubMed ID: 38310574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-181a reduces radiosensitivity of non-small-cell lung cancer via inhibiting PTEN.
    Chen Y; Liao W; Yuan A; Xu H; Yuan R; Cao J
    Panminerva Med; 2022 Sep; 64(3):374-383. PubMed ID: 32506887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A.
    Gu G; Hu C; Hui K; Zhang H; Chen T; Zhang X; Jiang X
    Int J Nanomedicine; 2021; 16():6329-6343. PubMed ID: 34556984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced miR-363-3p expression in non-small cell lung cancer is associated with gemcitabine resistance via targeting of CUL4A.
    Bian WG; Zhou XN; Song S; Chen HT; Shen Y; Chen P
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):649-659. PubMed ID: 30720173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-6077 enhances the sensitivity of patients-derived lung adenocarcinoma cells to anlotinib by repressing the activation of glucose transporter 1 pathway.
    Ma DB; Qin MM; Shi L; Ding XM
    Cell Signal; 2019 Dec; 64():109391. PubMed ID: 31421224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis
    Wu M; Jin MM; Cao XH; Zhao L; Li YH
    Curr Cancer Drug Targets; 2024; 24(4):445-454. PubMed ID: 37644752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-552-3p facilitated cell proliferation, migration and invasion by sponging Fibulin 5 in non-small cell lung cancer via activation of ERK/GSK3β/β-catenin signaling pathway.
    Huang M; Liao X; Li L; Li G; Chen M
    Tissue Cell; 2021 Dec; 73():101672. PubMed ID: 34736163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis.
    Chu D; Li P; Li Y; Shi J; Huang S; Jiao P
    Thorac Cancer; 2021 Nov; 12(21):2894-2906. PubMed ID: 34523261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
    Li Q; Wang Y; He J
    J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells.
    Zhao L; Wu X; Zhang Z; Fang L; Yang B; Li Y
    Cancer Sci; 2023 Jun; 114(6):2650-2663. PubMed ID: 36846943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
    Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y
    Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiroRNA-31-3p Promotes the Invasion and Metastasis of Non-Small-Cell Lung Cancer Cells by Targeting Forkhead Box 1 (FOXO1).
    Zeng X; Liu D; Peng G; Liu J; Yang H
    Comput Math Methods Med; 2022; 2022():4597087. PubMed ID: 35126623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circ_0020123 enhances the cisplatin resistance in non-small cell lung cancer cells partly by sponging miR-140-3p to regulate homeobox B5 (HOXB5).
    Wei D; Zeng J; Rong F; Xu Y; Wei R; Zou C
    Bioengineered; 2022 Mar; 13(3):5126-5140. PubMed ID: 35170372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib.
    Gu G; Hu C; Hui K; Chen T; Zhang H; Jiang X
    Aging (Albany NY); 2021 May; 13(10):13941-13953. PubMed ID: 33982669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of miR-144-3p exacerbates non-small cell lung cancer progression by targeting CEP55.
    Li M; Liu Y; Jiang X; Hang Y; Wang H; Liu H; Chen Z; Xiao Y
    Acta Biochim Biophys Sin (Shanghai); 2021 Oct; 53(10):1398-1407. PubMed ID: 34435195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circ_CSPP1 Regulates the Development of Non-small Cell Lung Cancer via the miR-486-3p/BRD9 Axis.
    Xie D; Zhang S; Jiang X; Huang W; He Y; Li Y; Chen S; Xiong H
    Biochem Genet; 2023 Feb; 61(1):1-20. PubMed ID: 35678942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.